NCT07267091

Brief Summary

This study aims to capture the Canadian patient experience, burden, barriers, and treatment preferences. The findings will generate real-world evidence to support patient-centered care and guide healthcare providers, researchers, and decision-makers in improving support and treatment for people living with lupus.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
88

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Nov 2025

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 3, 2025

Completed
21 days until next milestone

First Submitted

Initial submission to the registry

November 24, 2025

Completed
11 days until next milestone

First Posted

Study publicly available on registry

December 5, 2025

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 23, 2026

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 23, 2026

Completed
Last Updated

January 29, 2026

Status Verified

January 1, 2026

Enrollment Period

3 months

First QC Date

November 24, 2025

Last Update Submit

January 27, 2026

Conditions

LupusLupus ArthritisLupus Arthritis, Systemic Lupus ErythematosusQuality of Life (QOL)

Keywords

lupusquality of lifereal-world

Outcome Measures

Primary Outcomes (1)

  • To estimate quality of life of patients with lupus

    Using the 36-item Short Form (SF-36) questionnaire, a generic health-related quality of life questionnaire containing 8 domains. Each domains score ranges from 0 to 100, where 0 represents poor health and 100 best possible health.

    At recruitment

Secondary Outcomes (2)

  • To estimate work productivity impairment of patients with lupus.

    At recruitment

  • Indirect Costs and Patients' Preference Questionnaire

    At recruitment

Study Arms (1)

Patients with lupus

Adult patients with lupus member of Lupus Canada database

Other: No Intervention: Observational Cohort

Interventions

No Intervention: Observational CohortOTHER

No specific intervention is assess in this study. Observational cohort.

Patients with lupus

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients with Lupus who are part of Lupus Canada database

You may qualify if:

  • years of age or older;
  • Part of the Lupus Canada database;
  • a. Self-identified as a patient with Lupus.
  • Ability to read and understand English or French;
  • Signature of informed consent form.

You may not qualify if:

  • \. Participation in an interventional clinical trial for Lupus.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

PROxy Network, an initiative of PeriPharm Inc.

Montreal, Quebec, H2Y 1V3, Canada

Location

MeSH Terms

Conditions

Lupus Erythematosus, Systemic

Condition Hierarchy (Ancestors)

Connective Tissue DiseasesSkin and Connective Tissue DiseasesAutoimmune DiseasesImmune System Diseases

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 24, 2025

First Posted

December 5, 2025

Study Start

November 3, 2025

Primary Completion

January 23, 2026

Study Completion

January 23, 2026

Last Updated

January 29, 2026

Record last verified: 2026-01

Data Sharing

IPD Sharing
Will not share

Locations

CA(1)